Author Index Volume 23 (2011)

The issue number is given in front of the page numbers

Abbott F.M., M.N. Graham Dukes, Global Pharmaceutical Policy – Ensuring medicines for tomorrow’s world (1) 43–49
Abbela, M., see Abou-Hussein, S. (4) 241–248
Abou-Hussein, S., C. Savona-Ventura, S. Grima and A. Felice, Genetic factors in risk assessment for the development of type 2 diabetes mellitus in a small case series (2) 119–123
Abou-Hussein, S., M. Abela and C. Savona-Ventura, Body Mass Index adjustment for sitting height for better assessment of obesity risks in Maltese women (4) 241–248
Adeyemi, O.A., see Awodele, O. (4) 217–226
Akhtar, S., see Saddichha, S. (3) 181–185
Akinyede, A., see Awodele, O. (4) 217–226
Awodele, D.F., see Awodele, O. (4) 217–226
Awodele, O., A. Akinyede, O.A. Adeyemi and D.F. Awodele, Pharmacovigilance amongst doctors in private hospitals in Lagos West Senatorial District, Nigeria (4) 217–226
Bandekar, M.S., see Anwikar, S.R. (3) 163–169
Bavdekar, S.B., see Gogtay, N.J. (1) 1–3
Belefquih, B., see Tagajdid, M.R. (4) 249–254
Bella, M.M., see Yousif, M.A. (1) 11–16
Bencheikh, R.S., see Benabdallah, G. (1) 17–29
Benkirane, R., see Benabdallah, G. (1) 17–29
Bijl, D., H. Schellekens, The sponsored pandemic of the Mexican flu? (2) 73–79
Bijl, D., Pandemic influenza vaccines and neuraminidase inhibitors: Efficacy and side effects (2) 65–71
Breggin, P.R., Psychiatric drug-induced Chronic Brain Impairment (CBI): Implications for long-term treatment with psychiatric medication (4) 193–200
Casalegno, J.S., see Tagajdid, M.R. (4) 249–254
Chandler, P., A. Herxheimer, Unexpected aggressive behaviour: Interaction of bupropion and alcohol (3) 133–137
Chopra, D., N. Wardhan and H.S. Rehan, Knowledge, attitude and practices associated with adverse drug reaction reporting amongst doctors in a teaching hospital (4) 227–232
Dewey, H., see Williams, L. (3) 139–147
Doblali, T., see Tagajdid, M.R. (4) 249–254

Edwards, I.R., see Benabdallah, G. (1) 17–29
Edwards, I.R., see Body, D. (1) 31–42
El Annaz, H., see Tagajdid, M.R. (4) 249–254
Elmustafa, M.O., see Yousif, M.A. (1) 11–16

Felice, A., see Abou-Hussein, S. (2) 119–123

Go, K.H., see Body, D. (1) 31–42
Gogtay, N.J., S.B. Bavdekar, Assessment of safety and tolerability of local application of DEBA cream in infants and children (1) 1–3
Gøtzsche, P., see Nielsen, M. (2) 125–132
Graham, M.N., see Abbott F.M. (1) 43–49
Grima, S., see Abou-Hussein, S. (2) 119–123

Hama, R., M. Jones, H. Okushima, M. Kitao, N. Noda, K. Hayashi and K. Sakaguchi, Oseltamivir and early deterioration leading to death: A proportional mortality study for 2009A/H1N1 influenza (4) 201–215
Hassen, P., No. 5, October 2010, WHO Patient Safety Newsletter Progress in quality and patient safety: Are we at a tipping point? (1) 51–61
Hayashi, K., see Hama, R. (4) 201–215
Healy, D., Science, rhetoric and the causality of adverse events (3) 149–162
Healy, D., see Body, D. (1) 31–42
Henry, D., Doctors and drug companies: Still cozy after all these years (1) 7–10
Herxheimer, A., see Ziganshina, L.E. (3) 187–192
Hill, R., New vaccine reports from FDA to the Uppsala Monitoring Centre (2) 117–118
Jones, M., see Hama, R. (4) 201–215

Kapp, M.B., see Williams, L. (3) 139–147
Khattabi, A., see Benabdallah, G. (1) 17–29
Kitao, M., see Hama, R. (4) 201–215
Kohler, J.C., see Lexchin, J. (4) 233–240
Kshirsagar, N.A., see Anwikar, S.R. (3) 163–169

Labadie, J., Postlicensure safety evaluation of human papilloma virus vaccines (2) 103–112
Labadie, J., Vaccine safety news, (2) 113–115

Marks, D.H., Neurological complications of vaccination with outer surface protein A (OspA) (2) 89–96
Mekki, Y., see Tagajdid, M.R. (4) 249–254
Menkes, D.B., see Ziganshina, L.E. (3) 187–192
Mohiuddin, S., see Rajesh, R. (3) 171–180
Mrani, S., see Tagajdid, M.R. (4) 249–254
Mustafa, M.I., see Yousif, M.A. (1) 11–16

Nielsen, M., P. Gøtzsche, An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products (2) 125–132
Nizar, S., see Yousif, M.A. (1) 11–16
Noda, N., see Hama, R. (4) 201–215
Noorunnisa, see Rajesh, R. (3) 171–180

Okushima, H., see Hama, R. (4) 201–215

Pazare, A.P., see Anwikar, S.R. (3) 163–169
Polyakova, I.P., see Sychev, D.A. (1) 5–6

Rajesh, R., S. Vidyasagar, D.M. Varma, S. Mohiuddin and Noorunnisa, Evaluation of incidence of zidovudine induced anemia in Indian human immunodeficiency virus positive patients in comparision with stavudine based highly active antiretroviral therapy (3) 171–180
Rehan, H.S., see Chopra, D. (4) 227–232

Saddichha, S., G. Vishnuvardhan and S. Akhtar, Obesity, diabetes and hypertension associated with antipsychotic use in remitted schizophrenia (3) 181–185
Sakaguchi, K., see Hama, R. (4) 201–215
Savona-Ventura, C., see Abou-Hussein, S. (2) 119–123
Savona-Ventura, C., see Abou-Hussein, S. (4) 241–248
Schellekens, H., see Bijl, D. (2) 73–79
Semenov, A.V., see Sychev, D.A. (1) 5–6
Smrati, B., see Anwikar, S.R. (3) 163–169
Sychev, D.A., A.V. Semenov and I.P. Polyakova, A case of hepatic injury suspected to be caused by Canephron N, a Centaurium Hill containing phytotherapeutics (1) 5–6

Tatke, P.A., see Anwikar, S.R. (3) 163–169

van Grootheest, A.C., see van Puijenbroek, E.P. (2) 81–87
van Puijenbroek, E.P., A.C. van Grootheest, Monitoring adverse events of vaccines against Mexican flu (2) 81–87
Varma, D.M., see Rajesh, R. (3) 171–180
Viboud, C., L. Simonsen, Does seasonal influenza vaccination increase the risk of illness with the 2009 A/H1N1 pandemic virus? (2) 97–102
Vidyasagar, S., see Rajesh, R. (3) 171–180
Vishnuvardhan, G., see Saddichha, S. (3) 181–185

Wardhan, N., see Chopra, D. (4) 227–232
Williams, L., H. Dewey and M.B., Kapp, Long-term complication: Florida’s death certification process and long-term care (3) 139–147

Yousif, M.A., S. Nizar, M.O. Elmustafa, M.I. Mustafa and M.M. Bella, Investigation of medication prescribing errors in Wad Medani, Gezira, Sudan (1) 11–16